Recombinant Pongo abelii Dynamin-like 120 kDa protein, mitochondrial (OPA1)

Protein Overview

Recombinant Pongo abelii OPA1 is a dynamin-related GTPase with a molecular weight of approximately 120 kDa. The commercially available form typically consists of 50 μg quantities stored in Tris-based buffer with 50% glycerol for stability . The amino acid sequence exhibits the characteristic domains of the dynamin superfamily, including the GTPase domain critical for its function. The full protein spans amino acids 195-960 of the reference sequence and contains multiple functional domains that facilitate its various mitochondrial activities .

Cristae Architecture Regulation

Beyond its fusion activity, OPA1 serves as a key architect of the inner mitochondrial membrane's cristae structure. The protein forms oligomeric complexes through the interaction of two L-OPA1 molecules with one S-OPA1 molecule, which then stabilize the cristae junctions . This structural regulation is fundamentally important for maintaining efficient oxidative phosphorylation, as proper cristae formation optimizes the assembly and function of respiratory complexes and supercomplexes within the inner membrane.

Bioenergetic Pathway Modulation

Recent metabolomic studies have demonstrated that OPA1 disruption leads to significant remodeling of cellular bioenergetic pathways. Specifically, OPA1 absence affects aspartate metabolism and related metabolites, with notable decreases in aspartate, glutamate, and α-ketoglutaric acid levels, alongside increases in asparagine, glutamine, and adenosine-5'-monophosphate concentrations . These metabolic alterations indicate OPA1's broader role in regulating mitochondrial substrate utilization and energy production beyond its structural functions.

Expression Systems

Recombinant Pongo abelii OPA1 is typically produced using advanced mammalian cell expression systems, which ensure proper post-translational modifications and protein folding. This approach yields protein with characteristics more closely resembling the native form compared to bacterial expression systems. The production process typically involves gene optimization, transfection into mammalian host cells, and subsequent protein purification steps .

Purification and Quality Assessment

Commercial preparations of recombinant Pongo abelii OPA1 undergo rigorous purification protocols to ensure high quality. Standard quality control measures include:

The final product is typically supplied in a stabilized form, either as a liquid in PBS buffer or as a lyophilized powder, with recommendations for storage at -20°C to -80°C for long-term stability .

Sequence Homology

The Pongo abelii OPA1 protein shares significant sequence homology with its human counterpart, reflecting the evolutionary conservation of this critical mitochondrial protein. This high degree of conservation makes the Sumatran orangutan variant a valuable model for studying human OPA1-related functions and pathologies. Key differences in specific amino acid residues may provide insights into species-specific adaptations in mitochondrial dynamics.

Functional Conservation

Studies indicate that the fundamental functions of OPA1 are well-conserved between Pongo abelii and humans. Both proteins regulate mitochondrial fusion, maintain cristae structure, and contribute to respiratory chain supercomplex assembly . This functional conservation extends to the protein's role in protecting against apoptosis by preventing cytochrome c release and reducing reactive oxygen species production. The preservation of these critical functions across species underscores the evolutionary importance of OPA1 in mitochondrial homeostasis.

Mitochondrial Dynamics Studies

Recombinant Pongo abelii OPA1 serves as an invaluable tool for investigating the molecular mechanisms of mitochondrial fusion. Researchers utilize this protein in reconstitution experiments, binding assays, and structural studies to elucidate how OPA1 mediates fusion events and interacts with other components of the mitochondrial fusion machinery. These investigations provide critical insights into the fundamental processes governing mitochondrial network maintenance.

Bioenergetic Research

The protein has proven useful in studies exploring the relationship between mitochondrial structure and bioenergetic function. Research has demonstrated that OPA1 plays a critical role in regulating respiratory supercomplexes assembly and organization, with direct implications for oxidative phosphorylation efficiency . The protein's influence extends to mitochondrial swelling responses and permeability transition pore (PTP) function, highlighting its multifaceted role in mitochondrial physiology.

Disease Modeling

Recombinant OPA1 proteins enable the development of in vitro models for studying mitochondrial pathologies. Particularly relevant are investigations into dominant optic atrophy (DOA) and related disorders, where OPA1 mutations lead to mitochondrial dysfunction and subsequent neurodegeneration . By comparing wild-type and mutant forms, researchers can characterize the molecular consequences of pathogenic variations and identify potential therapeutic targets.

Association with Optic Atrophy

Mutations in the OPA1 gene are strongly associated with dominant optic atrophy (DOA), a condition characterized by progressive loss of visual acuity . The OPA1 database currently documents 516 unique OPA1 variants observed in 831 patients, with the majority of these variants (414) classified as pathogenic . Understanding the structure-function relationships of OPA1 through studies with the recombinant protein contributes to elucidating the molecular basis of these conditions.

Extended Neurological Phenotypes

Beyond classical DOA, OPA1 mutations can lead to a spectrum of neurological disorders collectively known as "DOA plus" syndromes. These expanded phenotypes include sensorineural hearing loss, ataxia, sensorimotor neuropathy, progressive external ophthalmoplegia, and mitochondrial myopathy . Research utilizing recombinant OPA1 proteins helps characterize how specific mutations affect protein function and contribute to this diverse clinical spectrum.

Potential Therapeutic Strategies

Recent research has explored therapeutic approaches for OPA1-related disorders, including the development of splice-switching antisense oligonucleotides like STK-002, which reduces poison exon inclusion in the OPA1 transcript, potentially leading to increased functional OPA1 protein levels . Recombinant Pongo abelii OPA1 serves as a valuable tool in screening and validating such therapeutic strategies before clinical testing.

Metabolomic Profiling

Recent metabolomic studies have revealed a distinct bioenergetic signature associated with OPA1 disruption. This signature is characterized by alterations in aspartate metabolism, impaired nucleotide synthesis, and compromised NAD metabolism . These findings suggest broader metabolic consequences of OPA1 dysfunction beyond direct effects on mitochondrial structure and highlight potential metabolic targets for therapeutic intervention in OPA1-related disorders.

Database Development and Variant Analysis

The evolution of the OPA1 database towards the Global Variome shared Leiden Open-source Variation Database (LOVD) format has enhanced the systematic documentation of OPA1 variants and associated phenotypes . This standardized approach facilitates interoperability with other genetic databases and supports large-scale mutation statistics and genotype-phenotype correlations, providing a valuable resource for researchers utilizing recombinant OPA1 proteins in their investigations.